SELLAS Life Sciences Group (NASDAQ:SLS) Sees Large Volume Increase – Still a Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) shares saw an uptick in trading volume on Wednesday. 12,230,612 shares changed hands during trading, an increase of 46% from the average daily volume of 8,360,633 shares. The stock last traded at $19.7250 and had previously closed at $19.15.

Top SELLAS Life Sciences Group Stories

Investors following SLS have been watching these stories:

  • Positive Sentiment: SELLAS said its pivotal REGAL trial of galinpepimut-S (GPS) in a specific group of patients with acute myeloid leukemia met its primary endpoint. GPS was associated with a 41% lower risk of death and median overall survival of 24 months, versus 14.7 months with best available treatment; the company also reported no new safety signals. SELLAS REGAL trial announcement
  • Neutral Sentiment: SLS also moved above its 200-day moving average, a technical milestone that may attract investor attention but does not establish a fundamental outlook. SLS moving-average article
  • Negative Sentiment: SELLAS proposed a $150 million underwritten public offering. Issuing additional shares can dilute existing investors and may weigh on the stock, particularly after its rally. Proposed public offering

Analysts Set New Price Targets

SLS has been the subject of a number of analyst reports. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Read Our Latest Stock Report on SLS

SELLAS Life Sciences Group Stock Up 4.4%

The firm has a market cap of $4.08 billion, a price-to-earnings ratio of -100.06 and a beta of 2.73. The company’s 50-day moving average price is $11.01 and its 200-day moving average price is $8.87.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05).

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in shares of SELLAS Life Sciences Group by 86.6% in the first quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock worth $2,023,000 after acquiring an additional 221,957 shares during the last quarter. Bank of America Corp DE raised its stake in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares during the last quarter. Dagco Inc. raised its stake in SELLAS Life Sciences Group by 19.8% in the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after purchasing an additional 203,653 shares during the last quarter. Wellington Management Group LLP lifted its holdings in SELLAS Life Sciences Group by 73.2% in the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after purchasing an additional 252,531 shares in the last quarter. Finally, Quantinno Capital Management LP acquired a new stake in SELLAS Life Sciences Group during the 1st quarter worth $315,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.

Featured Stories

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.